Evidence map›Paper›PMID 41167672›Full record

ArticleIn vivo (Athens, Greece)

Impact of Cyclin-dependent Kinase Inhibitor 1A Genotypes on Prostate Cancer Susceptibility Prediction.

Cheng-Hsi Liao, DA-Tian Bau, Bo-Ren Wang, Shu-Yu Chang, Te-Chun Hsia, Hsu-Tung Lee, Jaw-Chyun Chen, Wen-Chin Huang, Chia-Wen Tsai, Yun-Chi Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cheng-Hsi Liao *Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
DA-Tian Bau *Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Bo-Ren Wang *Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Shu-Yu ChangGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Te-Chun HsiaTerry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Hsu-Tung LeeDivision of Neurosurgical Oncology, Department of Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
Jaw-Chyun ChenDepartment of Medicinal Botanicals and Foods on Health Applications, Da-Yeh University, Changhua, Taiwan, R.O.C.
Wen-Chin HuangGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Chia-Wen TsaiGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Yun-Chi WangGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Hou-Yu ShihGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Wen-Shin ChangGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.; 031002@tool.caaumed.org.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimProstate cancer is a multifactorial disease influenced by both genetic and environmental factors. Previous studies have identified a correlation between p21 expression and the clinical severity of prostate cancer. However, the contribution of PATIENTS AND

methodsA total of 218 patients with prostate cancer and 436 cancer-free controls were genotyped for

resultsNo significant association was observed between either

conclusionWhile

Indexed as

Cyclin-Dependent Kinase Inhibitor p21Genetic Predisposition to DiseaseGenotypePolymorphism, Single NucleotideProstatic NeoplasmsAgedAllelesCase-Control StudiesGenetic Association StudiesHumansMaleMiddle AgedOdds RatioRisk FactorsTaiwanCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Agecyclin-dependent kinase inhibitor 1Agenotypepolymorphismprostate cancersmoking

Identifiers

PMID41167672
PMCPMC12588234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.